Search
Influenza A virus A/District of Columbia/27/2023 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB22669ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses.
Synonyms: Influenza A virus A/District of Columbia/27/2023 (H3N2) recombinant hemagglutinin antigenInfluenza A virus A/Victoria/800/2024 CVR-289 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB22671ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses.
Categories: Inactivated Influenza A Virus VaccineSynonyms: Influenza A virus A/Victoria/800/2024 CVR-289 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)Influenza A virus A/Perth/722/2024 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB31654ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses.
Categories: Live Attenuated Influenza A Virus VaccineSynonyms: Influenza A virus A/Perth/722/2024 (H3N2) live (attenuated) antigenOlodaterol
go.drugbank.com/drugs/DB09080ApprovedInvestigationalA once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period … Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs.
Glasdegib
go.drugbank.com/drugs/DB11978ApprovedInvestigationalGlasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. … [A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML).
Sodium hydroxide
go.drugbank.com/drugs/DB11151ApprovedAccording to the the FDA, sodium hydroxide is considered a direct food recognized as safe, where it serves as a pH control agent and follows good manufacturing guidelines [L1967]. … Sodium hydroxide is generally used as a solid or a diluted in a 50% solution. This chemical is used to manufacture soaps, rayon, paper, explosives, dyestuffs, and petroleum products [L1965].
Categories: Compounds used in a research, industrial, or household settingRurioctocog alfa pegol
go.drugbank.com/drugs/DB16007ApprovedInvestigationalIt was first approved by the European Commission in January 2018. … [L40119] Rurioctocog alfa pegol is a covalent conjugate of [octocog alfa], which is a recombinant factor VIII produced by recombinant DNA technology from a Chinese hamster ovary cell line.
Synonyms: Antihemophilic factor (recombinant), pegylated (20 kda)Linvoseltamab
go.drugbank.com/drugs/DB17447ApprovedInvestigationalFDA in July 2025 for patients who have undergone four or more prior lines. Continued approval in the U.S. is contingent upon verification of clinical benefit in a confirmatory trial. [L53363] … [L53353] It received conditional marketing authorization in the European Union in April 2025 for patients with three or more prior lines of therapy, [L53358] and was granted accelerated approval by the
Donislecel
go.drugbank.com/drugs/DB17961Approved[L47196] Donislecel was approved by the FDA on June 28, 2023, and is available under the brand name LANTIDRA from CellTrans Inc.[L47196] … [L47196] Overall, 21 patients achieved insulin independence for a year or more, with 11 patients not needing insulin for 1 to 5 years and 10 patients for more than 5 years.
Elexacaftor
go.drugbank.com/drugs/DB15444ApprovedInvestigational[L9395] Elexacaftor is considered a next-generation CFTR corrector as it possesses both a different structure and mechanism as compared to first generation correctors like tezacaftor. … Elexacaftor (previously VX-445) is a small molecule, next-generation corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.